InSysBio to take part in PAGE 2021

events
Conference
August 18, 2021

August 18, 2021

InSysBio announces its participation in PAGE 2021 Online meeting which is to be held on the 2nd, 3rd, 6th, and 7th of September 2021. InSysBio team is going to present its latest development at the Virtual Exhibition e-booth and six posters, namely:

Poster session 1.
Friday, Sep 3, 2021,
12:00 PM - 1:00 PM

Poster session 2.
Monday, Sep 6, 2021,
12:00 PM - 1:00 PM

Visit our booth and follow our presenters!

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

May 2023
MoTuWeThFrSaSu
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1. 30 May 2023 16:16 InSysBio to present a poster at PAGE Meeting 2023 InSysBio announces its participation in the 31st PAGE Meeting 2023 which is to be held at the Palexco Convention and Exhibition Centre, A Coruna, Spain on June 28-30, 2023. InSysBio team presents a poster within its frames
31
    
Upcoming Events
Tags
Latest News
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator
06.04
InSysBio to release Immune Response Template 3.6.2 for QSP modeling
16.01
InSysBio team to publish the new article “Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study”